Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 418 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neonatal Respiratory Distress Syndrome Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prophylactic Minimally Invasive Surfactant Evaluation

NCT06007547
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Premature Birth
Interventions
Poractant Alfa
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
Up to 15 Minutes
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 21, 2026, 6:19 AM EDT
Completed No phase listed Observational

Observational Crossover Study Comparing Oxygenation and Ventilation Using SiPAP Versus CPAP in LBW Infants

NCT01053455
View directory record Official record
Conditions
Ventilation, Respiratory Distress Syndrome
Interventions
SiPAP
Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 21, 2026, 6:19 AM EDT
Completed No phase listed Observational

Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury

NCT00980915
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 21, 2026, 6:19 AM EDT
Not listed Not applicable Interventional

Non-invasive Fluid Management

NCT02892799
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
NICOM-Guided Diuresis, Standard of Care
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 21, 2026, 6:19 AM EDT
Terminated Not applicable Interventional

Feasibility and Impact of Volume Targeted Ventilation in the Delivery Room

NCT03938532
View directory record Official record
Conditions
Prematurity, BPD - Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Newborn
Interventions
Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor, Tidal Volume Measurement using the Philips Respironics NM3 monitor
Device
Lead sponsor
Baystate Medical Center
Other
Eligibility
5 Minutes to 60 Minutes
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 21, 2026, 6:19 AM EDT
Not listed Phase 1Phase 2 Interventional

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

NCT04798716
View directory record Official record
Conditions
Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
Drug
Lead sponsor
AVEM HealthCare
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Panorama City, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 21, 2026, 6:19 AM EDT
Recruiting Not applicable Interventional

Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration

NCT07442669
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
Interventions
Lung ultrasound
Diagnostic Test
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
27 Weeks to 34 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 6:19 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19

NCT04778059
View directory record Official record
Conditions
2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection, Respiratory Distress Syndrome, Adult, Adult Respiratory Distress Syndrome
Interventions
USB002, Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 21, 2026, 6:19 AM EDT
Withdrawn Phase 2 Interventional

Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation

NCT00793013
View directory record Official record
Conditions
Acute Lung Injury, Adult Respiratory Distress Syndrome, Kidney Injury
Interventions
Volume-Cycled Assist-Control (AC) mode, Airway Pressure Release Ventilation (APRV) mode
Device
Lead sponsor
University of Tennessee, Chattanooga
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 21, 2026, 6:19 AM EDT
Not listed No phase listed Observational

Application of Lung Near-Infrared Spectroscopy (NIRS) in Preterm Infants

NCT05961670
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Neer Infrared Spectroscopy
Device
Lead sponsor
Keck School of Medicine of USC
Other
Eligibility
1 Hour to 24 Hours
Enrollment
50 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 21, 2026, 6:19 AM EDT
Not yet recruiting Not applicable Interventional

ADINA vs. High Flow Nasal Cannula Comparison Study

NCT03171129
View directory record Official record
Conditions
Respiratory Distress Neonatal
Interventions
Adaptive Dynamic Inspiratory Nasal Apparatus, High flow Nasal Canula
Device
Lead sponsor
Loma Linda University
Other
Eligibility
23 Weeks to 40 Weeks
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 21, 2026, 6:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

NCT04311697
View directory record Official record
Conditions
Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
Interventions
Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care
Drug
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 100 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 21, 2026, 6:19 AM EDT
Withdrawn Not applicable Interventional

Assessment of Occult Lung Stress During Lung Protective Mechanical Ventilation

NCT05675696
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Esophageal Catheter
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 21, 2026, 6:19 AM EDT
Withdrawn Phase 1 Interventional

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

NCT04522817
View directory record Official record
Conditions
Covid-19
Interventions
CLBS119
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 21, 2026, 6:19 AM EDT
Enrolling by invitation Not applicable Interventional

Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants

NCT07176117
View directory record Official record
Conditions
Respiratory Distress Syndrome (Neonatal), Surfactant
Interventions
Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA), Continuous Positive Airway Pressure (CPAP)
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
33 Weeks to 38 Weeks
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Chula Vista, California • La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

NCT04351243
View directory record Official record
Conditions
COVID-19
Interventions
Gimsilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 21, 2026, 6:19 AM EDT
Completed Not applicable Interventional

Mechanical Ventilation, Directed by Esophageal Pressure Measurements, in Patients With Acute Lung Injury

NCT00127491
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Placement of an esophageal balloon measurements, Low tidal volume ventilation, Transpulmonary pressure-directed ventilation (EPVent)
Procedure · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 21, 2026, 6:19 AM EDT
Terminated Phase 3 Interventional

INR-Triggered Transfusion In GI Bleeders From ER

NCT01461889
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Gastrointestinal Hemorrhage, Liver Diseases, Transfusion Related Lung Injury
Interventions
Transfuse plasma to High INR target, Transfuse plasma to Low INR target
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 21, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of UC-MSCs for COVID-19 Patients

NCT04355728
View directory record Official record
Conditions
Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
Biological · Other
Lead sponsor
Camillo Ricordi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 21, 2026, 6:19 AM EDT
Completed No phase listed Observational

Viral-Related Neutrophil Response and Condition Severity in People With ARDS

NCT00548795
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 21, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
View directory record Official record
Conditions
COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions
LSALT peptide, Placebo
Drug
Lead sponsor
Arch Biopartners Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 21, 2026, 6:19 AM EDT
Recruiting Phase 2 Interventional

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Infections
Interventions
Rhu-pGSN, normal saline
Drug
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 6:19 AM EDT
Enrolling by invitation Not applicable Interventional

Safety and Efficacy of Low-Flow ECMO in a Multi-modal Cohort of Adults in Respiratory Failure

NCT06938217
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure, Mechanical Ventilation, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Low-flow ECMO
Device
Lead sponsor
Institute for Extracorporeal Life Support
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 21, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

NCT04388826
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Veru-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Scottsdale, Arizona • Saint Louis Park, Minnesota • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 21, 2026, 6:19 AM EDT